In conclusion, this study adds new information on ECS alterations in normal or pathological aging and, on the basis of the relationship between the brain and the periphery in AD, it also suggests a possible role for FAAH not only as a peripheral biomarker but also as new possible therapeutic target for AD. This evidence concerns the gene FAAH and Alzheimer disease.